Safety and immunogenicity of a polyvalent peptide C4-V3 HIV vaccine in conjunction with IL-12.

Published

Journal Article

We examined the safety and immunogenicity of a human leukocyte antigen-based HIV envelope polyvalent synthetic peptide vaccine, C4-V3, alone and in combination with subcutaneous IL-12 in nine HIV-infected patients. Lymphocyte proliferative responses increased threefold or more to all four peptides at two consecutive post-immunization timepoints for four individuals. Three responders had received IL-12, suggesting a possible adjuvant effect of Il-12. Transient mild injection site reactions (7.9) and systemic symptoms (3/9) occurred.

Full Text

Duke Authors

Cited Authors

  • Sha, BE; Onorato, M; Bartlett, JA; Bosch, RJ; Aga, E; Nokta, M; Adams, EM; Li, X-D; Eldridge, J; Pollard, RB

Published Date

  • May 21, 2004

Published In

Volume / Issue

  • 18 / 8

Start / End Page

  • 1203 - 1206

PubMed ID

  • 15166537

Pubmed Central ID

  • 15166537

International Standard Serial Number (ISSN)

  • 0269-9370

Digital Object Identifier (DOI)

  • 10.1097/00002030-200405210-00015

Language

  • eng

Conference Location

  • England